Corcept Therapeutics Incorporated. (CORT)

Corcept Therapeutics' stock price has experienced significant volatility in the past six months. On December 31, 2025, the stock plunged after receiving a Complete Response Letter from the FDA for relacorilant, needing additional effectiveness data. In early January 2026, the stock continued to decline, prompting investigations into potential securities law violations. On November 4, 2025, the company announced Q3 2025 financial results, reporting revenue of $207.6 million and net income of $19.7 million, noting robust growth in patient volume and tablet shipments, but also acknowledged pharmacy capacity constraints. On July 31, 2025, Corcept missed Wall Street's revenue expectations for Q2 2025, lowering its full-year revenue guidance, but the market responded positively to management's explanation of pharmacy fulfillment issues. On March 31, 2025, the stock surged after announcing positive Phase 3 Rosella Trial results for relacorilant in patients with platinum-resistant ovarian cancer.

Corcept Therapeutics has experienced robust growth in patient demand and tablet shipments for its products. Specific details regarding the seasonal patterns of demand are not directly provided. The company has faced operational challenges related to pharmacy fulfillment issues, which have impacted reported revenue despite strong underlying demand.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing medications that modulate cortisol effects to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Their flagship product is Korlym, an FDA-approved oral therapy for controlling hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who also have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery. The company has a pipeline of investigational drugs, including relacorilant for hypercortisolism and platinum-resistant ovarian cancer, Rosella and Bella for ovarian cancer, Dazals for ALS, and miricorilant for NASH and antipsychotic-induced weight gain.

Corcept Therapeutics, Inc. is headquartered in Redwood City, California, United States. The company's operations and commercialization efforts are primarily focused in the United States, with regulatory submissions also extending to Europe for pipeline products like relacorilant.

Corcept Therapeutics' brand reputation has been significantly impacted by the FDA's Complete Response Letter for relacorilant, which led to a substantial drop in the company's stock price and raised concerns about its future growth strategy. The regulatory setback also triggered investigations into potential securities fraud. Prior to this, positive Phase 3 trial results for relacorilant in platinum-resistant ovarian cancer had boosted the company's reputation.

Corcept Therapeutics, Inc. has a mixed ownership structure. Institutions hold a substantial portion of the company's stock, with major institutional owners including BlackRock, Inc., Vanguard Group Inc., Ingalls & Snyder Llc, Renaissance Technologies Llc, iShares Core S&P Small-Cap ETF (IJR), State Street Corp, and Fmr Llc. Insiders hold a significant stake, with Patrick G. Enright being the largest individual shareholder and Joseph K. Belanoff, the CEO, also holding a significant stake. Recent insider trading activity has shown net selling of shares. The general public, primarily individual investors, holds a stake as well.